Meridian Bioscience Receives CE Marking for Two New Molecular Amplification Tests: illumigene® Chlamydia and illumigene® Gonorrhea
"Finally, there is a molecular platform in the market place that can
decentralize testing that is typically done in core reference
laboratories, and can be done so in a cost effective manner,” said Mike
Shaughnessy, Executive Vice President and President of Meridian Global
Diagnostics. “Meridian expects these two new illumigene tests,
along with the innovative
Chlamydia trachomatis and Neisseria gonorrhoeae are the
most common bacterial sexually transmitted infections worldwide.
The illumigene CT & NG assays utilize endocervical swabs, self-collected vaginal swabs, and female and male urine, making collection easy and non-invasive for physicians and patients. The test procedure is universal for all specimen types, and takes less than one hour to report a final result. Unlike other molecular systems, the illumigene platform requires no expensive capital equipment, and no costly annual service contracts. The performance and simplicity of this technology, along with its cost efficiency and small footprint, makes these new assays ideal for enabling a more rapid diagnosis.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive Officer, 513-271-3700